Organization of treatment and rehabilitation in Germany.
Complete medical support.
Complete medical support.
+49 176 17917001
All departments
Osteomyelitis is an infectious-inflammatory bone disease affecting bone marrow, compact bone, and periosteum. Without adequate treatment, it leads to bone destruction, sequestrum formation, fistulae, and can threaten the limb and life. Treatment in Germany includes targeted antibiotic therapy, surgical debridement, and innovative MIBRAR® therapy for bone regeneration after infection clearance.
Infection reaches bone through three pathways: hematogenous (via bloodstream — more common in children and elderly with spondylodiscitis), post-traumatic/post-surgical (after open fractures, osteosynthesis, joint replacement — the most common form in adults), and contiguous (spreading from adjacent soft tissues in diabetic foot, pressure ulcers, trophic ulcers). Common pathogens include Staphylococcus aureus (60–70%), coagulase-negative staphylococci (implant-associated), gram-negative bacteria, anaerobes, and mycobacteria.
Acute osteomyelitis (<2 weeks) presents without sequestra or fistulae and is treated with antibiotics ± abscess drainage. Subacute (2 weeks–3 months) involves abscess formation (Brodie's abscess) requiring antibiotics plus surgery. Chronic (>3 months) features sequestra, fistulae, and bone sclerosis mandating surgical debridement plus prolonged antibiotics. Implant-associated infection around hardware or prostheses often requires implant removal.
Risk factors include open fractures (especially Gustilo III with up to 30% osteomyelitis risk), hardware implantation surgery, diabetes (diabetic foot), immunosuppression (HIV, chemotherapy, corticosteroids), peripheral vascular disease, intravenous drug use, chronic wounds and pressure ulcers, and sickle cell disease (Salmonella in children).
Acute osteomyelitis presents with intense limb pain unrelieved by rest, fever (38–40°C) with chills and sweating, swelling, redness, and local warmth, limited movement and limping, and general malaise. Chronic osteomyelitis characteristically features a draining sinus with purulent discharge, periodic flares with fever, chronic pain, pathological fractures through weakened bone, and nonunion in infection-associated fractures.
Laboratory tests show elevated ESR (90%), CRP (most sensitive marker), leukocytes, and procalcitonin, with blood cultures. MRI provides early diagnosis (bone marrow edema visible from day 3–5) with 90–95% sensitivity, visualizing abscesses, fistulae, and sequestra. CT details sequestra for surgical planning. PET/CT with 18F-FDG assesses activity in chronic cases. Bone biopsy is mandatory for microbiological and histological examination — culture before antibiotics. Pathogen identification is the key to targeted treatment.
Antibiotic therapy is the foundation but insufficient without surgery in chronic cases. Empiric therapy starts after culture sampling with anti-staphylococcal antibiotics IV. Targeted therapy follows pathogen identification and sensitivity testing. Duration is 4–6 weeks IV for acute and 6–12 weeks (IV + oral) for chronic. Rifampicin is the key drug for destroying staphylococcal biofilms in chronic and implant-associated infections.
Mandatory for chronic osteomyelitis following the principle: radical debridement + defect filling + stabilization. Sequestrectomy removes all nonviable (dead) bone until the "paprika sign" — bleeding healthy bone. Defect filling uses antibiotic-loaded cement spacers (PMMA), autologous bone grafting, or the Masquelet induced membrane technique for large defects. Hardware removal addresses implant-associated infection with re-osteosynthesis after clearance. Bone transport (Ilizarov method) gradually "grows" new bone for large segmental defects. Soft tissue coverage with muscle flaps closes defects and improves blood supply.
Osteomyelitis (Osteomyeliten) is included in the indications for MIBRAR® technology, applied after active infection clearance during the bone restoration phase. ARC stimulates osteogenesis in bone defects after sequestrectomy as mesenchymal stem cells differentiate into osteoblasts. ARC has proven antimicrobial action (per Prof. Babayan's book). It treats post-infection nonunion without repeat major surgery. Soft tissue regeneration restores damaged muscles and skin in the surgical zone. The procedure uses microperforations plus ARC transplantation under Sono Control Arm™ or fluoroscopic guidance, outpatient and without anesthesia, strictly after verified clearance (normalized CRP, clean biopsy).
| Service | Price, € | Note |
|---|---|---|
| Diagnostics (MRI + biopsy + labs) | 4,000–8,000 | 2–3 days |
| Inpatient antibiotics (4–6 wks) | 12,000–25,000 | inpatient |
| Surgical debridement + reconstruction | 15,000–35,000 | 7–21 days inpatient |
| MIBRAR® therapy (after clearance) | on request | outpatient |
All treatment prices in Germany.
Germany offers specialized septic departments with multidisciplinary teams, precise microbiological diagnosis including biofilm detection, radical surgical debridement plus modern reconstruction (Masquelet, Ilizarov), MIBRAR® therapy for post-clearance bone regeneration plus antimicrobial effect, international antibiotic therapy protocols, and multilingual assistance at German clinics. Osteomyelitis requires expert management — contact us for specialized center treatment in Germany.
+49 176 17917001 
Or send us a message:
